Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline E Ford

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Cancers|October 14, 2022
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalTao Xie, Kristie-Ann Dickson, Christine Yee, et al.
Scientific Reports|March 2, 2018
I-AbACUS: a Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell AssaysMarilisa Cortesi, Estelle Llamosas, Claire E Henry, et al.
Frontiers in Pharmacology|December 19, 2025
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a targetKate Gunther, Dongli Liu, Gill Stannard, et al.
BMC Cancer|July 22, 2016
ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migrationSean S Q Ma, Sameer Srivastava, Estelle Llamosas, et al.
Scientific Reports|August 19, 2020
ROR1 is upregulated in endometrial cancer and represents a novel therapeutic targetDongli Liu, Kate Gunther, Luis A Enriquez, et al.
Molecular Oncology|August 8, 2024
Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancerBonnita Werner, Elyse Powell, Jennifer Duggan, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical modelsDongli Liu, Cassandra J Vandenberg, Patrizia Sini, et al.
Virchows Archiv : an International Journal of Pathology|September 16, 2016
Validation of specificity of antibodies for immunohistochemistry: the case of ROR2Sean S Q Ma, Claire E Henry, Estelle Llamosas, et al.
Translational Oncology|February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trialBonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
Molecular Therapy. Oncology|January 13, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerBayley Matthews, Michelle Wong-Brown, Dongli Liu, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Cancers|October 14, 2022
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalTao Xie, Kristie-Ann Dickson, Christine Yee, et al.
Scientific Reports|March 2, 2018
I-AbACUS: a Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell AssaysMarilisa Cortesi, Estelle Llamosas, Claire E Henry, et al.
Frontiers in Pharmacology|December 19, 2025
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a targetKate Gunther, Dongli Liu, Gill Stannard, et al.
BMC Cancer|July 22, 2016
ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migrationSean S Q Ma, Sameer Srivastava, Estelle Llamosas, et al.
Scientific Reports|August 19, 2020
ROR1 is upregulated in endometrial cancer and represents a novel therapeutic targetDongli Liu, Kate Gunther, Luis A Enriquez, et al.
Molecular Oncology|August 8, 2024
Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancerBonnita Werner, Elyse Powell, Jennifer Duggan, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical modelsDongli Liu, Cassandra J Vandenberg, Patrizia Sini, et al.
Virchows Archiv : an International Journal of Pathology|September 16, 2016
Validation of specificity of antibodies for immunohistochemistry: the case of ROR2Sean S Q Ma, Claire E Henry, Estelle Llamosas, et al.
Translational Oncology|February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trialBonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
Molecular Therapy. Oncology|January 13, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerBayley Matthews, Michelle Wong-Brown, Dongli Liu, et al.
Pageof 5